A Randomized, Double-Blind, Placebo-Controlled Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Healthy Volunteers and Psoriatic Patients and Clinical Proof-of-Concept in Psoriatic Patients

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Healthy Volunteers and Psoriatic Patients and Clinical Proof-of-Concept in Psoriatic Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Dec 2016

At a glance

  • Drugs VTP 43742 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Vitae Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Sep 2016 According to an Allergan media release, status changed from active, no longer recruiting to completed.
    • 17 May 2016 Results of this and other study (see profile 252360) presented at the IMMUNOLOGY 2016™ American Association of Immunologists Annual Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top